Vibalogics, a global contract development and manufacturing organization (CDMO), initiated the first stage of a $50 million investment at its Cuxhaven, Germany facility, expanding early-to-late phase clinical virotherapy manufacturing capacity.   The investment by the CDMO, which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products includes the expansion of the cGMP facility exceeding an overall 100,000 square feet to service process de...